Scilex Holding Company
SCLXHealthcareNASDAQDrug Manufacturers - General · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Scilex Holding Company focuses on Drug Manufacturers - General services and products. Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The company carries a $16.5M market cap, placing it firmly in the micro-cap category. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Market Cap
$16.5M
Beta
1.79
P/E (TTM)
—
P/E (Fwd)
3.22
EPS (TTM)
$-49.70
EPS (Fwd)
$0.73
ROE
—
ROA
-105.8%
Cash
$581,000
Total Debt
$106.0M
Free CF
-$8.8M
52W Change
-80.1%
Annual Financials
Cash vs Debt
Where SCLX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, SCLX finished 52.67% below its 150-day moving average ($5.43) and 53.86% below its 200-day moving average ($5.57). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SCLX overbought or oversold?
At the October 20, 2026 close, SCLX's RSI(14) was 11.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Scilex Holding Company carries $106.0M in total debt against $581K in cash reserves — debt is roughly 182.4x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company is burning cash, with free cash flow at -$8.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Revenue has been uneven over recent years, ranging from $38.0M to $30.3M.
Scilex Holding Company's elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Scilex Holding Company and its sector.